Every dollar amount and date on this page is quoted from the official settlement document.
Adamas Securities Litigation
Adamas Pharmaceuticals and a former executive settled a securities fraud lawsuit alleging false statements about reimbursement for its drug GOCOVRI. The $4,650,000 settlement fund paid eligible shareholders an average of about $0.27 per damaged share. The claim-filing window closed in 2024.
Official eligibility wordingPersons who purchased or otherwise acquired the publicly traded common stock of Adamas Pharmaceuticals, Inc. between August 8, 2017 and March 4, 2019, inclusive, and were damaged. Checked against the official settlement source by SettleSignal on June 19, 2026.
Key facts
- Who may qualify Anyone who bought or otherwise acquired Adamas Pharmaceuticals common stock between August 8, 2017 and March 4, 2019 and was financially harmed by the alleged false statements was covered by the settlement.
- Estimated payout$4,650,000 total settlement; estimated average recovery approximately $0.27 per eligible share
- Claim deadlineAugust 28, 2024 (closed)
- Proof requiredYes
- What you needThe claim deadline of August 28, 2024 has passed, and the settlement no longer accepts new claims.
- CourtUnited States District Court for the Northern District of California
Important dates
How hard is this claim to file?
Watch out for
- The Claim Form submission deadline has passed; check the settlement website for any court-ordered extensions before filing
- Doing nothing binds you to the settlement without any payment — you must actively file to receive compensation
- If you wanted to opt out and pursue separate legal action, the exclusion deadline has also passed
We prepare — you file on the official site yourself. This is not legal advice and is not an eligibility decision; the administrator and court decide.
Verify it yourself
How we verified this record
- Claim deadline Jun 19, 2026
- Payout details Jun 18, 2026
- Eligibility Jun 18, 2026
- Proof requirement Jun 18, 2026
- Administrator Jun 19, 2026
- Payment status Jun 19, 2026
- 2 fields queued for re-check
2 official sources linked to this record.
-
Claim deadline
August 28, 2024
Verified Jun 19, 2026
-
Eligibility summary Quoted in the official eligibility wording above ↑
Verified Jun 18, 2026
-
Proof requirement
Yes
Verified Jun 18, 2026
-
Payment status
Distribution complete
Verified Jun 19, 2026
-
Estimated payout
$4,650,000 total settlement; estimated average recovery approximately $0.27 per eligible share
Verified Jun 18, 2026
-
Administrator
Glancy Prongay & Murray LLP
Verified Jun 19, 2026
Lead Counsel is identified as Glancy Prongay & Murray LLP, with Leanne H. Solish listed as the primary contact attorney.
Show all 6 more verified fields
-
Objection deadline
September 6, 2024
Verified Jun 19, 2026
-
Opt-out deadline
September 6, 2024
Verified Jun 19, 2026
-
Class period start
August 8, 2017
Verified Jun 19, 2026
-
Class period end
March 4, 2019
Verified Jun 19, 2026
-
Court
United States District Court for the Northern District of California
Verified Jun 19, 2026
-
Case name
Adamas Securities Litigation
Verified Jun 18, 2026
Where to act
